| Literature DB >> 29397290 |
Rebecca Ahrens-Nicklas1, Lars Schlotawa2, Andrea Ballabio3, Nicola Brunetti-Pierri4, Mauricio De Castro5, Thomas Dierks6, Florian Eichler7, Can Ficicioglu8, Alan Finglas9, Jutta Gaertner10, Brian Kirmse11, Joerg Klepper12, Marcus Lee13, Amber Olsen14, Giancarlo Parenti4, Arastoo Vossough15, Adeline Vanderver16, Laura A Adang17.
Abstract
Multiple sulfatase deficiency (MSD) is an ultra-rare neurodegenerative disorder that results in defective sulfatase post-translational modification. Sulfatases in the body are activated by a unique protein, formylglycine-generating enzyme (FGE) that is encoded by SUMF1. When FGE is absent or insufficient, all 17 known human sulfatases are affected, including the enzymes associated with metachromatic leukodystrophy (MLD), several mucopolysaccharidoses (MPS II, IIIA, IIID, IVA, VI), chondrodysplasia punctata, and X-linked ichthyosis. As such, individuals demonstrate a complex and severe clinical phenotype that has not been fully characterized to date. In this report, we describe two individuals with distinct clinical presentations of MSD. Also, we detail a comprehensive systems-based approach to the management of individuals with MSD, from the initial diagnostic evaluation to unique multisystem issues and potential management options. As there have been no natural history studies to date, the recommendations within this report are based on published studies and consensus opinion and underscore the need for future research on evidence-based outcomes to improve management of children with MSD.Entities:
Keywords: Care; Consensus; Leukodystrophy; Mucopolysaccharidoses; Multiple sulfatase deficiency; Outcomes; Prevention; Therapy
Mesh:
Substances:
Year: 2018 PMID: 29397290 PMCID: PMC6856873 DOI: 10.1016/j.ymgme.2018.01.005
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797